Prospective clinical validation of the invisionfirst-lung circulating tumor DNA assay for molecular profiling of patients with advanced nonsquamous non–small-cell lung cancer

Michael A. Pritchett, D. Ross Camidge, Manu Patel, Jamil Khatri, Steven Boniol, Elke K. Friedman, Abderrahim Khomani, Samir Dalia, Katherine Baker-Neblett, Vincent Plagnol, Karen D. Howarth, Gregory R. Jones, Nitzan Rosenfeld, Clive D. Morris, Ramaswamy Govindan

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

PURPOSE Guidelines advocate molecular profiling in the evaluation of advanced non–small-cell lung cancer (NSCLC) and support the use of plasma circulating tumor DNA (ctDNA)-based profiling for patients with insufficient tissue. Thorough prospective clinical validation studies of next-generation sequencing (NGS)-based ctDNA assays are lacking. We report the multicentered prospective clinical validation of the InVision ctDNA assay in patients with advanced untreated NSCLC. METHODS A total of 264 patients with untreated advanced NSCLC were prospectively recruited, and their plasma was analyzed using a ctDNA NGS assay for detection of genomic alterations in 36 commonly mutated genes. Tumor tissue was available in 178 patients for molecular profiling for comparison with plasma profiling. The remaining 86 patients were included to compare ctDNA profiles in patients with and without tissue for profiling. RESULTS Concordance of InVisionFirst with matched tissue profiling was 97.8%, with 82.9% positive predictive value, 98.5% negative predictive value, 70.6% sensitivity, and 99.2% specificity. Considering specific alterations in eight genes that most influence patient management, the positive predictive value was 97.8%, with 97.1% negative predictive value, 73.9% sensitivity, and 99.8% specificity. Across the entire study, 48 patients with actionable alterations were identified by ctDNA testing compared with only 38 by tissue testing. ctDNA NGS reported either an actionable alteration or an alteration generally considered mutually exclusive for such actionable changes in 53% of patients. CONCLUSION The liquid biopsy NGS assay demonstrated excellent concordance with tissue profiling in this multicenter, prospective, clinical validation study, with sensitivity and specificity equivalent to Food and Drug Administration–approved single-gene ctDNA assays. The use of plasma-based molecular profiling using NGS led to the detection of 26% more actionable alterations compared with standard-of-care tissue testing in this study.

Original languageEnglish
JournalJCO Precision Oncology
Volume3
DOIs
StatePublished - Jan 1 2019

Fingerprint Dive into the research topics of 'Prospective clinical validation of the invisionfirst-lung circulating tumor DNA assay for molecular profiling of patients with advanced nonsquamous non–small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Pritchett, M. A., Camidge, D. R., Patel, M., Khatri, J., Boniol, S., Friedman, E. K., Khomani, A., Dalia, S., Baker-Neblett, K., Plagnol, V., Howarth, K. D., Jones, G. R., Rosenfeld, N., Morris, C. D., & Govindan, R. (2019). Prospective clinical validation of the invisionfirst-lung circulating tumor DNA assay for molecular profiling of patients with advanced nonsquamous non–small-cell lung cancer. JCO Precision Oncology, 3. https://doi.org/10.1200/PO.18.00299